Relationship of SNCG, S100A4, S100A9 and LCN2 gene expression and DNA methylation in bladder cancer

International Journal of Cancer

Volumn 123, Issue 12, 2008, Pages 2798-2807

  Dokun, Olusola Y ^a   Florl, Andrea R ^a   Seifert, Hans Helge ^a,b   Wolff, Ingmar ^a,c   Schulz, Wolfgang A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Bisulfite sequencing; DNA hypomethylation; Microarray; Primary cell culture; Urothelial cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CALGRANULIN B; CALVASCULIN; CYTOKERATIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; DNA METHYLATION; FEMALE; FIBROBLAST; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LEUKOCYTE; MALE; MICROARRAY ANALYSIS; ONCOGENE; PRIORITY JOURNAL; SNCG GENE; UROTHELIUM;

ACUTE-PHASE PROTEINS; CALGRANULIN B; CELL LINE, TUMOR; DNA METHYLATION; GAMMA-SYNUCLEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOCALINS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; S100 PROTEINS; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 57349163599     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23893     Document Type: Article

References (50)

1. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002;21:5400-13.
2. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683-92.
3. Hoffmann MJ, Schulz WA. Causes and consequences of DNA hypomethylation in human cancer. Biochem Cell Biol 2005;83:296-321.
4. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta 2007;1775:138-62.
5. Picard V, Bergeron A, Larue H, Fradet Y. MAGE-A9 mRNA and protein expression in bladder cancer. Int J Cancer 2007;120:2170-7.
6. Gupta A, Godwin AK, Vanderveer L, Lu A, Liu J. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res 2003;63:664-73.
7. Yanagawa N, Tamura G, Honda T, Endoh M, Nishizuka S, Motoyama T. Demethylation of the synuclein gamma gene CpG island in primary gastric cancers and gastric cancer cell lines. Clin Cancer Res 2004;10:2447-51.
8. Liu H, Liu W, Wu Y, Zhou Y, Xue R, Luo C, Wang L, Zhao W, Jiang JD, Liu J. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Res 2005;65:7635-43.
9. Wu K, Quan Z, Weng Z, Li F, Zhang Y, Yao X, Chen Y, Budman D, Goldberg ID, Shi YE. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis. Breast Cancer Res Treat 2007;101:259-67.
10. Sato N, Maitra A, Fukushima N, van Heek NT, Matsubayashi H, Iacobuzio-Donahue CA, Rosty C, Goggins M. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 2003;63:3735-42.
11. Neuhausen A, Florl AR, Grimm MO, Schulz WA. DNA methylation alterations in urothelial carcinoma. Cancer Biol Ther 2006;5:993-1001.
12. Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA, Hamdy FC, Catto JW. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 2007;13:2046-53.
13. Jürgens B, Schmitz-Drager BJ, Schulz WA. Hypomethylation of L1 LINE sequences prevailing in human urothelial carcinoma. Cancer Res 1996;56:5698-703.
14. Del Senno L, Maestri I, Piva R, Hanau S, Reggiani A, Romano A, Russo G. Differential hypomethylation of the c-myc protooncogene in bladder cancers at different stages and grades. J Urol 1989;142:146-9.
15. Ogishima T, Shiina H, Breault JE, Terashima M, Honda S, Enokida H, Urakami S, Tokizane T, Kawakami T, Ribeiro-Filho LA, Fujime M, Kane CJ, Carroll PR, Igawa M, Dahiya R. Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer. Oncogene 2005;24:6765-72.
16. Thykjaer T, Workman C, Kruhoffer M, Demtröder K, Wolf H, Andersen LD, Frederiksen CM, Knudsen S, Orntoft TF. Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Res 2001;61:2492-9.
17. Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, Belbin TJ, Prystowsky MB, Ortiz AR, Childs G, Cordon-Cardo C. Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 2003;163:505-16.
18. Modlich O, Prisack HB, Pitschke G, Ramp U, Ackermann R, Bojar H, Vögeli TA, Grimm MO. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res 2004;10:3410-21.
19. Aaboe M, Marcussen N, Jensen KM, Thykjaer T, Dyrsköt L, Orntoft TF. Gene expression profiling of noninvasive primary urothelial tumours using microarrays. Br J Cancer 2005;93:1182-90.
20. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Carroll P, Waldman FM. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005;11:4044-55.
21. Kawakami K, Enokida H, Tachiwada T, Gotanda T, Tsuneyoshi K, Kubo H, Nishiyama K, Takiguchi M, Nakagawa M, Seki N. Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling. Oncol Rep 2006;16:521-31.
22. Diggle CP, Cruickshank S, Olsburgh JD, Pellegrin S, Smith B, Banks RE, Selby PJ, Knowles MA, Southgate J, Harnden P. Identification of genes up-regulated in urothelial tumors: the 67-kd laminin receptor and tumor-associated trypsin inhibitor. Am J Pathol 2003;163:493-504.
23. Baskin LS, Hayward SW, Sutherland RA, DiSandro MS, Thomson AA, Cunha GR. Cellular signaling in the bladder. Front Biosci 1997;2:592-5.
24. Southgate J, Hutton KA, Thomas DF, Trejdosiewicz LK. Normal human urothelial cells in vitro: proliferation and induction of stratification. Lab Invest 1994;71:583-94.
25. Seifert HH, Meyer A, Cronauer MV, Hatina J, Muller M, Rieder H, Hoffmann MJ, Ackermann R, Schulz WA. A new and reliable culture system for superficial low-grade urothelial carcinoma of the bladder. World J Urol 2007;25:297-302.
26. Davies BR, O'Donnell M, Durkan GC, Rudland PS, Barraclough R, Neal DE, Mellon JK. Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer. J Pathol 2002;196:292-9.
27. Agerbaek M, Alsner J, Marcussen N, Lundbeck F, Von der Maase H. Focal S100A4 protein expression is an independent predictor of development of metastatic disease in cystectomized bladder cancer patients. Eur Urol 2006;50:777-85.
28. Swiatkowski S, Seifert HH, Steinhoff C, Prior A, Thievessen I, Schliess F, Schulz WA. Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp Cell Res 2003;282:48-57.
29. Wlazlinski A, Engers R, Hoffmann MJ, Hader C, Jung V, Müller M, Schulz WA. Downregulation of several fibulin genes in prostate cancer. Prostate 2007;67:1770-80.
30. Hoffmann MJ, Florl AR, Seifert HH, Schulz WA. Multiple mechanisms downregulate CDKN1C in human bladder cancer. Int J Cancer 2005;114:406-13.
31. Hoffmann R, Valencia A. Implementing the iHOP concept for navigation of biomedical literature. Bioinformatics 2005;21:252-8.
32. Rabbani F, Richon VM, Orlow I, Lu ML, Drobnjak M, Dudas M, Charytonowicz E, Dalbagni G, Cordon-Cardo C. Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization. J Natl Cancer Inst 1999;91:874-81.
33. Varley C, Hill G, Pellegrin S, Shaw NJ, Selby PJ, Trejdosiewicz LK, Southgate J. Autocrine regulation of human urothelial cell proliferation and migration duringregenerative responses in vitro. Exp Cell Res 2005;306:216-29.
34. MacLaine NJ, Wood MD, Holder JC, Rees RW, Southgate J. Sensitivity of normal, parmalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway. Mol Cancer Res 2008;6:53-63.
35. Lobban ED, Smith BA, Hall GD, Harnden P, Roberts P, Selby PJ, Trejdosiewicz LK, Southgate J. Uroplakin gene expression by normal and neoplastic human urothelium. Am J Pathol 1998;153:1957-67.
36. Wu RL, Osman I, Wu XR, Lu ML, Zhang ZF, Liang FX, Hamza R, Scher H, Cordon-Cardo C, Sun TT. Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation. Cancer Res 1998;58:1291-7.
37. Ostergaard M, Rasmussen HH, Nielsen HV, Vorum H, Orntoft TF, Wolf H, Celis JE. Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. Cancer Res 1997;57:4111-7.
38. Konduri SD, Srivenugopal KS, Yanamandra N, Dinh DH, Olivero WC, Gujrati M, Foster DC, Kisiel W, Ali-Osman F, Kondraganti S, Lakka SS, Rao JS. Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. Oncogene 2003;22:4509-16.
39. Rosty C, Ueki T, Argani P, Jansen M, Yeo CJ, Cameron JL, Hruban RH, Goggins M. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol 2002;160:45-50.
40. Rehman I, Goodarzi A, Cross SS, Leiblich A, Catto JW, Phillips JT, Hamdy FC. DNA methylation and immunohistochemical analysis of the S100A4 calcium binding protein in human prostate cancer. Prostate 2007;67:341-7.
41. Weber M, Hellmann I, Stadler MB, Ramos L, Pääbo S, Rebhan M, Schübeler D. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007;39:457-66.
42. Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA, Hendrix MJ. The paradoxical expression of maspin in ovarian carcinoma. Clin. Cancer Res 2002;8:2924-32.
43. Lonardo F, Li X, Siddiq F, Singh R, Al-Abbadi M, Pass HI, Sheng S. Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer 2006;51:31-9.
44. Futscher BW, Oshiro MM, Wozniak RJ, Holtan N, Hanigan CL, Duan H, Domann FE. Role for DNA methylation in the control of cell type specific maspin expression. Nat Genet 2002;31:175-9.
45. Yao R, Lopez-Beltran A, Maclennan GT, Montinori R, Eble JN, Cheng L. Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res 2007;27:3051-8.
46. Tulchinsky E, Grigorian M, Tkatch T, Georgiev G, Lukanidin E. Transcriptional regulation of the mts1 gene in human lymphoma cells: the role of DNA-methylation. Biochim Biophys Acta 1995;1261:243-8.
47. Roll JD, Rivenbark AG, Jones WD, Coleman WB. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol Cancer 2008;7:15.
48. Reigstad CS, Hultgren SJ, Gordon JI. Functional genomic studies of uropathogenic Escherichia coli and host urothelial cells when intracellular bacterial communities are assembled. J Biol Chem 2007;282:21259-67.
49. Liang G, Gonzales FA, Jones PA, Orntoft TF, Thykjaer T. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res 2002;62:961-6.
50. Gebhardt C, Németh J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006;72:1622-31.